MicroRNAs in obesity-associated disorders

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

The emergence of a worldwide obesity epidemic has dramatically increased the prevalence of insulin resistance and metabolic syndrome, predisposing individuals to a greater risk for the development of non-alcoholic fatty liver disease, type II diabetes and atherosclerotic cardiovascular diseases. Current available pharmacological interventions combined with diet and exercise-based managements are still poorly effective for weight management, likely in part due to an incomplete understanding of regulatory mechanisms and pathways contributing to the systemic metabolic abnormalities under disturbed energy homeostasis. MicroRNAs, small non-coding RNAs that regulate posttranscriptional gene expression, have been increasingly described to influence shifts in metabolic pathways under various obesity-related disease settings. Here we review recent discoveries of the mechanistic role that microRNAs play in regulating metabolic functions in liver and adipose tissues involved in obesity associated disorders, and briefly discusses the potential candidates that are being pursued as viable therapeutic targets.

Original languageEnglish
Pages (from-to)108-119
Number of pages12
JournalArchives of Biochemistry and Biophysics
Volume589
DOIs
Publication statusPublished - 1 Jan 2016

Fingerprint

MicroRNAs
Obesity
Liver
Small Untranslated RNA
Nutrition
Medical problems
Metabolic Networks and Pathways
Gene expression
Type 2 Diabetes Mellitus
Insulin Resistance
Adipose Tissue
Homeostasis
Cardiovascular Diseases
Pharmacology
Insulin
Tissue
Diet
Gene Expression
Weights and Measures
Therapeutics

Keywords

  • Insulin resistance
  • Lipid/fat metabolism
  • Metabolic syndrome
  • MicroRNAs
  • Obesity
  • RNA therapeutics

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology

Cite this

MicroRNAs in obesity-associated disorders. / Abente, Eugenio J.; Subramanian, Murugan; Ramachandran, Vimal; Najafi, Hani.

In: Archives of Biochemistry and Biophysics, Vol. 589, 01.01.2016, p. 108-119.

Research output: Contribution to journalReview article

@article{025ee3f108a4491aae3461f53801102a,
title = "MicroRNAs in obesity-associated disorders",
abstract = "The emergence of a worldwide obesity epidemic has dramatically increased the prevalence of insulin resistance and metabolic syndrome, predisposing individuals to a greater risk for the development of non-alcoholic fatty liver disease, type II diabetes and atherosclerotic cardiovascular diseases. Current available pharmacological interventions combined with diet and exercise-based managements are still poorly effective for weight management, likely in part due to an incomplete understanding of regulatory mechanisms and pathways contributing to the systemic metabolic abnormalities under disturbed energy homeostasis. MicroRNAs, small non-coding RNAs that regulate posttranscriptional gene expression, have been increasingly described to influence shifts in metabolic pathways under various obesity-related disease settings. Here we review recent discoveries of the mechanistic role that microRNAs play in regulating metabolic functions in liver and adipose tissues involved in obesity associated disorders, and briefly discusses the potential candidates that are being pursued as viable therapeutic targets.",
keywords = "Insulin resistance, Lipid/fat metabolism, Metabolic syndrome, MicroRNAs, Obesity, RNA therapeutics",
author = "Abente, {Eugenio J.} and Murugan Subramanian and Vimal Ramachandran and Hani Najafi",
year = "2016",
month = "1",
day = "1",
doi = "10.1016/j.abb.2015.09.018",
language = "English",
volume = "589",
pages = "108--119",
journal = "Archives of Biochemistry and Biophysics",
issn = "0003-9861",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - MicroRNAs in obesity-associated disorders

AU - Abente, Eugenio J.

AU - Subramanian, Murugan

AU - Ramachandran, Vimal

AU - Najafi, Hani

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The emergence of a worldwide obesity epidemic has dramatically increased the prevalence of insulin resistance and metabolic syndrome, predisposing individuals to a greater risk for the development of non-alcoholic fatty liver disease, type II diabetes and atherosclerotic cardiovascular diseases. Current available pharmacological interventions combined with diet and exercise-based managements are still poorly effective for weight management, likely in part due to an incomplete understanding of regulatory mechanisms and pathways contributing to the systemic metabolic abnormalities under disturbed energy homeostasis. MicroRNAs, small non-coding RNAs that regulate posttranscriptional gene expression, have been increasingly described to influence shifts in metabolic pathways under various obesity-related disease settings. Here we review recent discoveries of the mechanistic role that microRNAs play in regulating metabolic functions in liver and adipose tissues involved in obesity associated disorders, and briefly discusses the potential candidates that are being pursued as viable therapeutic targets.

AB - The emergence of a worldwide obesity epidemic has dramatically increased the prevalence of insulin resistance and metabolic syndrome, predisposing individuals to a greater risk for the development of non-alcoholic fatty liver disease, type II diabetes and atherosclerotic cardiovascular diseases. Current available pharmacological interventions combined with diet and exercise-based managements are still poorly effective for weight management, likely in part due to an incomplete understanding of regulatory mechanisms and pathways contributing to the systemic metabolic abnormalities under disturbed energy homeostasis. MicroRNAs, small non-coding RNAs that regulate posttranscriptional gene expression, have been increasingly described to influence shifts in metabolic pathways under various obesity-related disease settings. Here we review recent discoveries of the mechanistic role that microRNAs play in regulating metabolic functions in liver and adipose tissues involved in obesity associated disorders, and briefly discusses the potential candidates that are being pursued as viable therapeutic targets.

KW - Insulin resistance

KW - Lipid/fat metabolism

KW - Metabolic syndrome

KW - MicroRNAs

KW - Obesity

KW - RNA therapeutics

UR - http://www.scopus.com/inward/record.url?scp=84950327231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84950327231&partnerID=8YFLogxK

U2 - 10.1016/j.abb.2015.09.018

DO - 10.1016/j.abb.2015.09.018

M3 - Review article

C2 - 26416722

AN - SCOPUS:84950327231

VL - 589

SP - 108

EP - 119

JO - Archives of Biochemistry and Biophysics

JF - Archives of Biochemistry and Biophysics

SN - 0003-9861

ER -